Celgene's most recent trend suggests a bearish bias. One trading opportunity on Celgene is a Bear Call Spread using a strike $160.00 short call and a strike $170.00 long call offers a potential 10.13% return on risk over the next 18 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $160.00 by expiration. The full premium credit of $0.92 would be kept by the premium seller. The risk of $9.08 would be incurred if the stock rose above the $170.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Celgene is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Celgene is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
How Are Earnings Panning Out in the Biotech Sector?
Wed, 05 Feb 2014 01:14:06 GMT
Motley Fool – The healthcare sector is off to another strong start in 2014. The question is whether this strength is the result of irrational exuberance among investors, or improving fundamentals. I dig into this issue …
World Cancer Day: A Single Day Is Never Enough
Tue, 04 Feb 2014 15:12:31 GMT
noodls – Spreading knowledge about cancer is important. Feb. 4, 2014 marks World Cancer Day, an initiative led by the Geneva-based Union for International Cancer Control (UICC). This year's movement aims to bust …
Stock Draft: Brian's Ballers vs. Mandy's Mavericks
Fri, 31 Jan 2014 19:48:00 GMT
CNBC – Six stocks, one winner. Who will be crowned champion? Reggie Middleton, BoomBustBlog.com; Guy Adami StockMonster.com; Jeff Kilburg, KKM Financial; Abigail Doolittle, Peak Theories; and Josh Brown, Ritholtz …
Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene?
Fri, 31 Jan 2014 19:12:00 GMT
TheStreet – A quick look at the biotech sector performance in the first month of 2014.
2014's Better Biotech Buy: Biogen Idec, Inc. vs. Amgen, Inc.
Fri, 31 Jan 2014 15:57:57 GMT
Motley Fool – Big biotech has surged in the past few years, with Biogen and Amgen among the two leaders in this industry. Which stock looks the best for investors in 2014?
Also on Market Tamer…
Follow Us on Facebook